357 related articles for article (PubMed ID: 15729207)
1. Surgical management of epithelial ovarian cancer: a review of the literature.
Dupont NC; Berman ML
Minerva Ginecol; 2004 Dec; 56(6):547-56. PubMed ID: 15729207
[TBL] [Abstract][Full Text] [Related]
2. Advances in treatment of epithelial ovarian cancer.
Kikkawa F; Nawa A; Ino K; Shibata K; Kajiyama H; Nomura S
Nagoya J Med Sci; 2006 Jan; 68(1-2):19-26. PubMed ID: 16579172
[TBL] [Abstract][Full Text] [Related]
3. Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?
Larsen E; Blaakaer J
Acta Obstet Gynecol Scand; 2009; 88(4):373-7. PubMed ID: 19253061
[TBL] [Abstract][Full Text] [Related]
4. [Time interval between ovarian cancer surgery and chemotherapy--secondary publication?].
Larsen EP; Blaakaer J
Ugeskr Laeger; 2009 Nov; 171(45):3265-8. PubMed ID: 19916194
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience.
Bilici A; Salepci T; Dane F; Gumus M; Ustaalioglu BB; Seker M; Salman T; Turan C; Unal O; Yaylaci M
Arch Gynecol Obstet; 2010 Oct; 282(4):417-25. PubMed ID: 20035339
[TBL] [Abstract][Full Text] [Related]
6. Optimal debulking surgery is an independent prognostic factor in patients with FIGO IIIC primary epithelial ovarian carcinoma.
Wang PH; Yuan CC; Shyong WY; Chiang SC; Chao JY; Yen MS; Ng HT
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):220-5. PubMed ID: 10746418
[TBL] [Abstract][Full Text] [Related]
7. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the management of women with ovarian cancer.
Eltabbakh GH
Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
[TBL] [Abstract][Full Text] [Related]
9. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
[TBL] [Abstract][Full Text] [Related]
10. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique).
Morice P; Leblanc E; Rey A; Baron M; Querleu D; Blanchot J; Duvillard P; Lhommé C; Castaigne D; Classe JM; Bonnier P;
Hum Reprod; 2005 May; 20(5):1379-85. PubMed ID: 15817592
[TBL] [Abstract][Full Text] [Related]
11. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
[TBL] [Abstract][Full Text] [Related]
12. [Cytoreductive surgery in the management of stage IV epithelial ovarian cancer].
Zang R; Zhang Z; Chen J
Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):197-9. PubMed ID: 11776157
[TBL] [Abstract][Full Text] [Related]
13. Retrospective study of the prognostic factors of remission induction for single-agent chemotherapy with cisplatin in advanced epithelial ovarian cancer.
Matsumoto Y; Deguchi M; Ishiko O; Ogita S
Oncol Rep; 2000; 7(2):311-3. PubMed ID: 10671677
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for ovarian cancer: an evidence-based approach.
Geisler JP; Manahan KJ; Wiemann MC
Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
[TBL] [Abstract][Full Text] [Related]
15. Management of early-stage epithelial ovarian cancer.
Benjamin I; Rubin SC
Obstet Gynecol Clin North Am; 1994 Mar; 21(1):107-19. PubMed ID: 8015759
[TBL] [Abstract][Full Text] [Related]
16. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
17. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
[TBL] [Abstract][Full Text] [Related]
18. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data.
Manci N; Bellati F; Muzii L; Calcagno M; Alon SA; Pernice M; Angioli R; Panici PB
Ann Surg Oncol; 2006 Dec; 13(12):1717-23. PubMed ID: 16957965
[TBL] [Abstract][Full Text] [Related]
19. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
Capizzi E; Gabusi E; Grigioni AD; De Iaco P; Rosati M; Zamagni C; Fiorentino M
Diagn Mol Pathol; 2008 Mar; 17(1):34-8. PubMed ID: 18303408
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
